Top Stories
-
Twenty years ago, Columbia scientists created a way to make neurons in a dish, a discovery that has led to clinical trials of an experimental drug that may slow the progression of ALS.
Topic
-
Using EEG to identify covert consciousness in unresponsive brain-injured patients could help predict which ones may recover, find researchers at Columbia and NewYork-Presbyterian.
Topic
-
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
Topic
-
A gene called FMNL2 may explain why people with hypertension, diabetes, heart disease, or obesity have a greater risk of developing Alzheimer's disease.
Topic
Latest News
- May 23, 2022
A transient ischemic attack (TIA) is a stroke that usually lasts under five minutes and resolves on its own, but just because the symptoms disappear, does not mean a TIA should be ignored.
- May 10, 2022
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
Topic
- March 30, 2022
Parkinson’s patients and their families are increasingly turning to genetic testing to learn more about their disease or risk of passing it on. But testing is complex, and counseling is advised.
Topic
- March 15, 2022
COVID patients who remain unresponsive after receiving respiratory support may require long time periods to regain consciousness; delays are related to blood oxygen levels.
Topic
- March 7, 2022
A newly discovered protein tangle has been associated with multiple neurodegenerative diseases and may have a role in causing the diseases.
Topic
- March 7, 2022
A one-hour time change may not seem like much but it causes health and sleep issues. Here's advice from Columbia doctors to minimize the effect.
Topic
- February 15, 2022
One of the cell's most common proteins may become too old and too stable in Alzheimer’s disease, altering neuronal activity and impairing memory.
Topic
- January 24, 2022
Based on Columbia research, an experimental drug for a rare type of ALS is being tested in a phase 3 clinical trial after a new study found that the drug lowered levels of a toxic protein.
Topic
- November 11, 2021
A study of more than 500 hospitalized COVID patients found that comorbidities do not necessarily result in the worst outcomes.
Topic
- November 1, 2021
Since 1955, “Merritt’s Neurology,” edited by Columbia neurologists, has been regarded as the standard reference work in the field. James Noble, MD, joins the ranks for the latest edition.
Topic
